Search Results73 results found
Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.
Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response
Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA)
Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.
Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives
Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology
New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform.
Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA)
Seqirus appoints Roberta Duncan as new program lead to drive sa-mRNA technology advancement. Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza.
Seqirus strengthens U.K. influenza vaccine response as high-speed fill and finish facility begins rolling 30 million doses in Liverpool
First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool.
EU Flu Day 2021 – Seqirus joins experts’ calls to boost vaccine uptake ahead of a second influenza season during the COVID-19 pandemic
A panel of leading international experts discuss the challenges of the oncoming influenza season at this year’s EU Flu Day